To request a grand rounds click here!
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.
Specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants.
At the conclusion of this activity, participants will be able to:
- Describe the pathophysiology of hyperkalemia in end stage renal disease (ESRD), especially in patients receiving hemodialysis, and discuss the immense morbidity and mortality implications of elevated predialysis K+ levels.
- Review traditional strategies for managing serum K+ in ESRD patients receiving dialysis and identify the pivotal shortcomings of these standard approaches.
- Examine novel pharmacologic treatment approaches for reducing the incidence of predialysis hyperkalemia, including an appraisal of completed and ongoing clinical trials and recent FDA approvals.
- Using a case-based format, apply evolving, interprofessional management strategies to prevent and manage hyperkalemia in ESRD patients receiving hemodialysis, with a focus on the promising role of K+ binders.
Csaba P. Kovesdy, MD
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clincial Trials Program
Division of Nephrology, University of Tennessee Health Science Center
Nephrology Section Chief, Memphis VA Medical Center
George Bakris, MD
Director, Am Heart Assoc. Comprehensive Hypertension Center
University of Chicago Medicine
Matthew R. Weir, MD
Director of the Division of Nephrology
Department of Medicine at the University of Maryland Hospital
Professor of Medicine at the University of Maryland School of Medicine
1-hour presentation providing up to 1.0 ACCME/ANCC/ACPE credit